Niagen Bioscience, Inc. Reports Third Quarter 2026 Financial Results
Business Wire•04/11/2026•16:02 ET
0
Key Highlights
- ➤Q3 net sales $27.2 million, including $23.3 million from Tru Niagen
- ➤Q3 net loss $1.2 million; adjusted EBITDA positive at $0.5 million
- ➤Q3 operating cash flow $2.6 million; cash reached $69.5 million
- ➤2026 website revenue growth forecast remains 15% to 20% year-over-year
- ➤Niagen Plus, skincare, Walmart.com, GNC, and Sam’s Club launches expand distribution
Expert Statements
Rob Fried, Chief Executive Officer of Niagen Bioscience
“During the third quarter, we navigated near-term commercial headwinds while continuing to generate positive adjusted EBITDA and $2.6 million in operating cash flow and make tangible progress across the Niagen platform”
Rob Fried, Chief Executive Officer of Niagen Bioscience
“We advanced NB4168, expanded Tru Niagen distribution, established skincare as a permanent category, launched a more convenient ready-to-inject Niagen Plus product, and invested in brand awareness and long-term clinical research.”
Rob Fried, Chief Executive Officer of Niagen Bioscience
“As stated before, we view 2026 as an investment year, and believe the progress we are making across consumer health, ingredients, injectables, skincare, and pharmaceuticals provides a strong springboard for meaningful growth in 2027 and beyond.”
Niagen Bioscience, Inc. Reports Third Quarter 2026 Financial Results
Launched Niagen NanoCloud™, the first dermatologist-tested topical product
Get started
Create a free account to read the full story.